Launched in 2020

lThe only new-generation varicella vaccine backed by evidence in phase III clinical efficacy results

lProtective efficacy of 89.2% against breakthrough cases, and 100% against moderate and severe cases

lSafer viral release enabled by physical technology, and formulation optimized to reduce pain.